---
layout: default
title: Sennosides
parent: Model Prediction Only (L5)
nav_order: 712
evidence_level: L5
indication_count: 6
---

# Sennosides
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **6** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Sennosides: From Constipation to Hypotrichosis Simplex of the Scalp

## One-Sentence Summary

> Sennosides is an anthraquinone-class stimulant laxative used to treat constipation.
> The TxGNN model's top prediction suggests possible relevance to **Hypotrichosis Simplex of the Scalp**,
> but this association is currently supported by **0 clinical trials** and **0 publications**, and the evidence pack's own mechanistic review concludes the signal is most likely knowledge-graph noise rather than genuine biological plausibility.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Constipation (anthraquinone stimulant laxative — inferred from rationale text; not present in `original_indications`) |
| Predicted New Indication | Hypotrichosis Simplex of the Scalp |
| TxGNN Prediction Score | 99.29% |
| Evidence Level | L5 |
| Canada Market Status | ✗ Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available from DrugBank for sennosides (flagged as a High-severity data gap, DG002). Based on the descriptive information available in the evidence pack, sennosides is an anthraquinone-class stimulant laxative that acts by stimulating the submucosal plexus of the colon, increasing peristalsis, and inhibiting water reabsorption in the large intestine.

This mechanism has no established connection to hair follicle biology, keratinocyte proliferation, androgen receptor signaling, T-cell–mediated autoimmune follicular attack, or trabecular meshwork/aqueous humor dynamics. All six of the model's top-ranked predictions cluster around two unrelated disease families — hair loss (hypotrichosis, alopecia areata, congenital hypotrichosis, alopecia) and glaucoma (open-angle, primary hereditary) — none of which share a plausible pharmacological pathway with a colonic stimulant laxative.

The evidence pack's own mechanistic rationale for every candidate explicitly concludes there is "no biological plausibility" and attributes the associations to TxGNN embedding artifacts, possibly arising from rare co-morbidity nodes in the knowledge graph rather than a true drug–disease signal.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for hypotrichosis simplex of the scalp.

*Note: Two trials were retrieved under the related candidate "alopecia" (rank 6), but both were assessed as irrelevant — one evaluated platelet-rich plasma injections (NCT05348343) and the other was an assessment-tool validation study with no drug intervention (NCT03082560). Neither involves sennosides.*

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

Sennosides currently has no licensed products in Canada (0 DINs; market status: Not Marketed).

---

## Safety Considerations

Please refer to the package insert for safety information. TFDA-equivalent labeling data (warnings, contraindications) is flagged as a **Blocking**-severity data gap (DG001) and has not yet been retrieved.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No clinical trials or literature evidence support any of the six predicted indications, and the mechanistic review — including the evidence pack's own analysis — indicates these are most likely TxGNN embedding noise rather than genuine repurposing signals. The drug is also not currently marketed in Canada, and core safety data (labeling, MOA) remain unresolved data gaps.

**To proceed, the following is needed:**
- Confirmed mechanism of action data from DrugBank (DG002)
- TFDA/Health Canada-equivalent labeling data — warnings and contraindications (DG001, Blocking)
- Independent literature or preclinical evidence directly linking sennosides to hair follicle or intraocular pressure pathways, to rule out embedding noise
- Reassessment of candidate ranking once real evidence becomes available; no action recommended until evidence level improves beyond L5
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

